5,7-Dihydroxy-4-Methylcoumarin

5,7-Dihydroxy-4-Methylcoumarin

SCHEMBL403833

Cc1cc(=O)oc2cc(O)cc(O)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 1.00
HPGD P15428 4/20 1.00
HSD17B10 Q99714 3/20 1.00
TSHR P16473 2/20 1.00
CASP1 P29466 2/20 1.00
CASP7 P55210 2/20 1.00
CA9 Q16790 2/20 1.00
CYP3A4 P08684 2/20 1.00
KDR P35968 3/20 0.67
NUAK1 O60285 2/20 0.67
IGF1R P08069 2/20 0.67
PIM1 P11309 2/20 0.67
SRC P12931 2/20 0.67
PLK1 P53350 2/20 0.67
PKN1 Q16512 2/20 0.67
AURKB Q96GD4 2/20 0.67
ALK Q9UM73 2/20 0.67
HTT P42858 3/20 0.62
CLK2 P49760 1/20 0.61
GAA P10253 5/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
5,7-Dihydroxy-4-Methylcoumarin SCHEMBL29431030 1.00 ALDH1A1 (1.00) ALDH1A1HPGDHSD17B10TSHRCASP1
5,7-Dihydroxy-4-Methylcoumarin SCHEMBL4395631 0.98 ALDH1A1 (0.96) ALDH1A1HPGDHSD17B10TSHRCASP1
SCHEMBL5118377 0.93 ALDH1A1 (0.86) ALDH1A1HPGDHSD17B10TSHRCASP1
SCHEMBL11215292 0.89 ALDH1A1 (0.79) ALDH1A1HPGDHSD17B10TSHRCASP1
SCHEMBL12457526 0.85 ALDH1A1 (0.74) ALDH1A1HPGDHSD17B10TSHRCASP1
Formaldehyde SCHEMBL27728506 0.85 ALDH1A1 (0.74) ALDH1A1HPGDHSD17B10TSHRCASP1
SCHEMBL536984 0.84 ALDH1A1 (0.72) ALDH1A1HPGDHSD17B10TSHRCASP1
SCHEMBL22031602 0.82 ALDH1A1 (0.70) ALDH1A1HPGDHSD17B10TSHRCASP1
SCHEMBL6904702 0.82 ALDH1A1 (0.70) ALDH1A1HPGDHSD17B10TSHRCASP1
SCHEMBL5337247 0.81 ALDH1A1 (0.69) ALDH1A1HPGDHSD17B10TSHRCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12421419-B2 Preparation method for ultraviolet-responsive coumarin controlled-release and self-repairing anti-fouling paint Quzhou Research Institute of Zhejiang University (CN) 2025-09-23 US claimed
WO-2024209462-A1 ANTI-BIOFILM POLYMER COMPOSITIONS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2024-10-10 WO claimed
CN-116333564-B Fluorescent epoxy emulsion, preparation method thereof and epoxy fluorescent paint 江苏丰彩建材(集团)有限公司 2024-02-02 CN claimed
CN-115124679-B Self-repairing hyperbranched waterborne polyurethane and preparation method and application thereof 陕西科技大学 2023-09-12 CN claimed
CN-116672289-A Leaf extract of white mustard and application thereof in preparing cosmetics 西藏藏医药大学 2023-09-01 CN claimed
CN-115851110-B Preparation method of light response long-acting super-lubricating anti-fouling paint based on coumarin 浙江大学 2023-08-15 CN claimed
CN-116478361-A Self-repairing antibacterial aqueous polyurethane and preparation method and application thereof 陕西科技大学 2023-07-25 CN claimed
US-20230212419-A1 PREPARATION METHOD FOR ULTRAVIOLET-RESPONSIVE COUMARIN CONTROLLED-RELEASE AND SELF-REPAIRING ANTI-FOULING PAINT Quzhou Research Institute of Zhejiang University (CN) 2023-07-06 US claimed
CN-116333564-A Fluorescent epoxy emulsion, preparation method thereof and epoxy fluorescent paint 江苏丰彩建材(集团)有限公司 2023-06-27 CN claimed
CN-115851110-A Preparation method of coumarin-based photoresponse long-acting super-lubricating antifouling paint 浙江大学 2023-03-28 CN claimed
WO-2017165464-A1 MULTISPECIFIC AND MULTIFUNCTIONAL MOLECULES AND USES THEREOF ELSTAR THERAPEUTICS, INC. (US) 2017-09-28 WO claimed
CN-104411324-A Combination therapy using anti-hyaluronan agents and tumor-targeted taxanes HALOZYME INC 2015-03-11 CN claimed
EP-2833905-A1 COMBINATION THERAPY WITH AN ANTI - HYALURONAN AGENT AND A TUMOR - TARGETED TAXANE Halozyme, Inc. (US) 2015-02-11 EP claimed
WO-2014062856-A1 HYPOXIA AND HYALURONAN AND MARKERS THEREOF FOR DIAGNOSIS AND MONITORING OF DISEASES AND CONDITIONS AND RELATED METHODS HALOZYME, INC. (US) 2014-04-24 WO claimed
WO-2013151774-A1 COMBINATION THERAPY WITH AN ANTI - HYALURONAN AGENT AND A TUMOR - TARGETED TAXANE HALOZYME, INC. (US) 2013-10-10 WO claimed
US-20120020951-A1 Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects HALOZYME, INC. 2012-01-26 US claimed
CN-101792472-A Method for synthesis of aryl rhamnoside UNIV EAST CHINA NORMAL 2010-08-04 CN claimed
WO-2006024545-A1 FUSED BICYCLIC NATURAL COMPOUNDS AND THEIR USE AS INHIBITORS OF PARP AND PARP-MEDIATED INFLAMMATORY PROCESSES STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) 2006-03-09 WO claimed
WO-1996031206-A2 FLAVONES AND COUMARINS AS AGENTS FOR THE TREATMENT OF ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-10-10 WO claimed
US-4128428-A ORGANIC SILVER SALT, N-HALO COMPOUND, REDUCING AGENT, IRON COMPOUND FUJI PHOTO FILM CO., LTD. (JP) 1978-12-05 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120020951-A1 Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects ENGASE, HPSE, GUSB ALDH1A1 474/4885HPGD 353/4885HSD17B10 367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.